Market research
ANR.AU Anatara Lifesciences Limited
AU AUD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 1.79
- Dividend yield
- Not available
- Beta
- 0.65
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000ANR0
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 1.79
- Dividend yield
- Not available
- Beta
- 0.65
About
About Anatara Lifesciences Limited
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include irritable bowel syndrome; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral complementary medication to assist weight reduction and control. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.
Research context
Anatara Lifesciences Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ANR.AU discussion.
5 years, 6 months ago
Anatara Lifesciences Limited is currently in a long term downtrend where the price is trading 4.9% below its 200 day moving average.
From a valuation standpoint, the stock is 97.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.3.
Anatara Lifesciences Limited's total revenue sank by 0.0% to $209K since the same quarter in the previous year.
Its net income has increased by 42.9% to $-1M since the same quarter in the previous year.
Finally, its free cash flow fell by 70.3% to $-948K since the same quarter in the previous year.
Based on the above factors, Anatara Lifesciences Limited gets an overall score of 2/5.